InsiderClue
Stocks · Health care · Pharmaceutical Preparations

AGIOS PHARMACEUTICALS, INC.

AGIO Clue Score43
United States Fiscal year ends December CIK 0001439222 Results filed 5 Nov 2026
Add to watchlist

What the insiders did Mostly scheduled

Individual transactions

40
Insider
Date
Role
Action
Shares
Price
Amount
Sarah Gheuens
26 Oct 2026
Chief Medical Officer
Sold after exercise
7,866
$37.69
$296.47K
Sarah Gheuens
22 Oct 2026
Chief Medical Officer
Sold after exercise
500
$37.52
$18.76K
Sarah Gheuens
21 Oct 2026
Chief Medical Officer
Sold after exercise
1,489
$37.53
$55.88K
Sarah Gheuens
1 Jul 2026
Chief Medical Officer
Sold after exercise
4,007
$37.56
$150.50K
Brian Goff
2 Apr 2026
Chief Executive Officer
Sold after exercise
6,596
$34.71
$228.95K
Brian Goff
2 Apr 2026
Chief Executive Officer
Sold after exercise
12,472
$34.71
$432.90K
Krishnan Viswanadhan
2 Apr 2026
Chief Corp Dev & Strategy
Sold after exercise
2,959
$34.71
$102.71K
Tsveta Milanova
2 Apr 2026
Chief Commercial Officer
Sold after exercise
3,262
$34.71
$113.22K
Cecilia Jones
2 Apr 2026
Chief Financial Officer
Sold after exercise
3,141
$34.71
$109.02K
Sarah Gheuens
2 Apr 2026
Chief Medical Officer
Sold after exercise
2,940
$34.71
$102.05K
James William Burns
2 Apr 2026
Chief Legal Officer
Sold after exercise
3,280
$34.71
$113.85K
Krishnan Viswanadhan
5 Mar 2026
Chief Corp Dev & Strategy
Sold after exercise
2,959
$27.80
$82.26K
Theodore James Washburn Jr.
2 Mar 2026
Principal Accounting Officer
Sold after exercise
798
$28.96
$23.11K
Theodore James Washburn Jr.
2 Mar 2026
Principal Accounting Officer
Sold after exercise
727
$28.96
$21.05K
Theodore James Washburn Jr.
2 Mar 2026
Principal Accounting Officer
Sold after exercise
698
$28.96
$20.21K
Tsveta Milanova
2 Mar 2026
Chief Commercial Officer
Sold after exercise
1,187
$28.96
$34.38K
Tsveta Milanova
2 Mar 2026
Chief Commercial Officer
Sold after exercise
1,681
$28.96
$48.68K
Cecilia Jones
2 Mar 2026
Chief Financial Officer
Sold after exercise
1,573
$28.96
$45.55K
Cecilia Jones
2 Mar 2026
Chief Financial Officer
Sold after exercise
1,187
$28.96
$34.38K
Cecilia Jones
2 Mar 2026
Chief Financial Officer
Sold after exercise
1,681
$28.96
$48.68K
Cecilia Jones
2 Mar 2026
Chief Financial Officer
Sold after exercise
594
$28.96
$17.20K
Sarah Gheuens
2 Mar 2026
Chief Medical Officer
Sold after exercise
1,187
$28.96
$34.38K
Sarah Gheuens
2 Mar 2026
Chief Medical Officer
Sold after exercise
1,681
$28.96
$48.68K
Sarah Gheuens
2 Mar 2026
Chief Medical Officer
Sold after exercise
1,187
$28.96
$34.38K
James William Burns
2 Mar 2026
Chief Legal Officer
Sold after exercise
1,163
$28.96
$33.68K
James William Burns
2 Mar 2026
Chief Legal Officer
Sold after exercise
1,187
$28.96
$34.38K
James William Burns
2 Mar 2026
Chief Legal Officer
Sold after exercise
1,681
$28.96
$48.68K
James William Burns
2 Mar 2026
Chief Legal Officer
Sold after exercise
1,187
$28.96
$34.38K
Brian Goff
2 Mar 2026
Chief Executive Officer
Sold after exercise
5,918
$28.96
$171.39K
Brian Goff
2 Mar 2026
Chief Executive Officer
Sold after exercise
8,267
$28.96
$239.41K
Brian Goff
2 Mar 2026
Chief Executive Officer
Sold after exercise
3,870
$28.96
$112.08K
Tsveta Milanova
5 Jan 2026
Chief Commercial Officer
Sold after exercise
2,872
$27.02
$77.60K
Cecilia Jones
30 Dec 2025
Chief Financial Officer
Sold after exercise
2,932
$27.09
$79.43K
Tsveta Milanova
30 Dec 2025
Chief Commercial Officer
Sold after exercise
2,932
$27.09
$79.43K
Sarah Gheuens
30 Dec 2025
Chief Medical Officer
Sold after exercise
2,932
$27.09
$79.43K
Brian Goff
30 Dec 2025
Chief Executive Officer
Sold after exercise
6,230
$27.09
$168.77K
Brian Goff
30 Dec 2025
Chief Executive Officer
Sold after exercise
12,473
$27.09
$337.89K
James William Burns
30 Dec 2025
Chief Legal Officer
Sold after exercise
2,932
$27.09
$79.43K
David Scadden
12 Nov 2025
Director
Sold after exercise
200
$43.84
$8.77K
Sarah Gheuens
11 Nov 2025
Chief Medical Officer
Sold after exercise
2,454
$43.78
$107.44K
Show all 42 transactions →

What was left out

Form 4 filings counted 45
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 1
Sales straight out of an exercise 40
Sales at will 1
Transactions with no price 0
Shares from compensation/vesting 313,674
History held since 30 Jul 2013